Women with more severe leakage at baseline improved significantly more when treated with the Internet-based programme compared with the postal programme.
During follow-up, all eyes without nerve branching pattern at baseline progressively developed it when treated with latanoprost, whereas no change occurred using tafluprost treatment (p = 0.05).
Specifically, a clinical response or remission was achieved in 53.1% of patients with a baseline CRP ≥10 mg/L when treated with CZP 400 mg, compared with 17.9% of patients who received placebo (P=0.005).
During infusion, rCBF compared to baseline was +1.2% ± 5.5 when treated with hαCGRP versus −1.6% ± 9.8 when treated with placebo.
At the last measurement during infusion, 15 min after its beginning, Vmean compared to baseline was −13.5% ± 11.4 when treated with hCGRP, versus 0.6% ± 5.6 when treated with placebo (P < 0.005, paired t test).
Previous studies have shown that patients with a high inflammatory burden at baseline experience greater improvement in vascular function when treated with anti-inflammatory drugs than do patients who have lower baseline inflammation [ 9, 29].
In conclusion, the survival benefit observed for PDAC patients with overexpression of ACOX1 in blood or reporting baseline pain of VAS > 20 mm when treated with masitinib plus gemcitabine, coupled with manageable toxicity suggests a positive benefit risk ratio.
The RCT by Long et al. [ 25, 26] concluded that patients with directional preference, including centralization, fared better 2 weeks after baseline than patients with no directional preference when treated with MDT in comparison with strengthening training.
Unlike SW13−/− cells, U373 MG cells formed a prominent stress fiber network at baseline and did not develop this network further when treated with nocodazole.
